Monoclonal antibodies are the most important type of biotechnological products after vaccines and recombinant proteins. They are the strategic commanding heights of biotechnology and biomedicine industries in the 21st century. After 35 years of development, monoclonal antibody technology has gone through four stages: murine, chimeric, humanized, and fully human monoclonal antibodies. In response to the COVID-19 outbreak, Creative Biolabs can provide the service of immunizing humanized antibody mice with SARS-CoV-2 surface protein to screen for therapeutic human monoclonal antibodies.
Creative Biolabs is providing monoclonal antibody screening services based on humanized antibody mice. We have self-cultivated humanized antibody mice, through the immunization of the S-RBD protein antigen, a dominant protein which is on the surface of the SARS-CoV-2 and plays a crucial role in mediating virus entry into target cell, and use the hybridoma fusion protocol to conduct the discovery study of human monoclonal antibodies for COVID-19 treatment. Through hybridoma fusion combined with semi-solid screening, we have screened a certain number of hybridoma cell lines that can efficiently bind S-RBD. Through the blocking experiment of RBD protein binding to ACE2, we further selected hybridoma clones with high blocking effect and high affinity for live virus neutralization experiments, and obtained hybridomas with live virus neutralization effect. The recombinantly expressed neutralizing antibody has better affinity and neutralizing activity than other neutralizing antibodies.
Fig.1 Flow of therapeutic human monoclonal antibodies screening.
Please feel free to contact us for more information.
For Research Use Only. We do not provide direct services or products for patients.Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.